IL147766A0 - Therapeutic compounds comprised of anti-fc receptor binding agents - Google Patents

Therapeutic compounds comprised of anti-fc receptor binding agents

Info

Publication number
IL147766A0
IL147766A0 IL14776600A IL14776600A IL147766A0 IL 147766 A0 IL147766 A0 IL 147766A0 IL 14776600 A IL14776600 A IL 14776600A IL 14776600 A IL14776600 A IL 14776600A IL 147766 A0 IL147766 A0 IL 147766A0
Authority
IL
Israel
Prior art keywords
receptor
molecules
antigen
cell
multispecific
Prior art date
Application number
IL14776600A
Other languages
English (en)
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/364,088 external-priority patent/US6365161B1/en
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of IL147766A0 publication Critical patent/IL147766A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14776600A 1999-07-30 2000-07-25 Therapeutic compounds comprised of anti-fc receptor binding agents IL147766A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/364,088 US6365161B1 (en) 1995-06-07 1999-07-30 Therapeutic compounds comprised of anti-FC receptor binding agents
US52327900A 2000-03-10 2000-03-10
PCT/US2000/020158 WO2001009186A2 (en) 1999-07-30 2000-07-25 Therapeutic compounds comprised of anti-fc receptor binding agents

Publications (1)

Publication Number Publication Date
IL147766A0 true IL147766A0 (en) 2002-08-14

Family

ID=27002335

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14776600A IL147766A0 (en) 1999-07-30 2000-07-25 Therapeutic compounds comprised of anti-fc receptor binding agents

Country Status (12)

Country Link
EP (1) EP1212366B1 (de)
JP (2) JP4308470B2 (de)
KR (1) KR100816958B1 (de)
CN (1) CN1268645C (de)
AT (1) ATE373017T1 (de)
AU (1) AU779116B2 (de)
CA (1) CA2381565A1 (de)
DE (1) DE60036388D1 (de)
HK (1) HK1049170A1 (de)
IL (1) IL147766A0 (de)
MX (1) MXPA02000960A (de)
WO (1) WO2001009186A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2437814C (en) 2001-02-12 2008-05-13 Medarex, Inc. Human monoclonal antibodies to fc alpha receptor (cd89)
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
ES2392525T3 (es) * 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
US20040146948A1 (en) * 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
BG65715B1 (bg) * 2003-09-04 2009-08-31 Чавдар ВАСИЛЕВ Средство за селективно подтискане на патологични днк - специфични в клетки
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
KR101430627B1 (ko) 2008-05-13 2014-08-14 유니버시티 오브 캔사스 금속 추출 펩타이드(ｍａｐ) 태그 및 관련된 방법
EA036225B1 (ru) * 2012-03-14 2020-10-15 Ридженерон Фармасьютикалз, Инк. Мультиспецифические антигенсвязывающие молекулы и их применения
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
US10117943B2 (en) * 2013-05-03 2018-11-06 Yale University Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer
PL405768A1 (pl) * 2013-10-24 2015-04-27 Celther Polska Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie agonistów EGFR i HGFR jako leków przeciwnowotworowych działających na komórki nowotworowe o określonym fenotypie
MX2017017117A (es) 2015-07-06 2018-03-06 Regeneron Pharma Moleculas multiespecificas de union a antigenos y usos de estas.
EP3352760A4 (de) 2015-09-21 2019-03-06 Aptevo Research and Development LLC Cd3-bindende polypeptide
EP3448891A1 (de) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Verfahren zur herstellung multispezifischer antigenbindender moleküle
EP3241847A1 (de) * 2016-05-06 2017-11-08 MAB Discovery GmbH Her-2-bindende antikörper
WO2018140845A2 (en) * 2017-01-27 2018-08-02 Duke University Bi-specific antibodies to cd64 and a disease antigen
WO2020091596A1 (en) * 2018-10-29 2020-05-07 Umc Utrecht Holding B.V. Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils
CA3131705A1 (en) 2019-03-27 2020-10-01 Umc Utrecht Holding B.V. Engineered iga antibodies and methods of use
EP4242233A1 (de) * 2020-11-06 2023-09-13 Korea University Research and Business Foundation Fc-alpha-rezeptorbindender antikörper

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0496818B1 (de) * 1989-10-20 1999-06-23 Trustees Of Dartmouth College Iga-rezeptorspezifische monoklonale antikörper
US6018031A (en) * 1989-10-20 2000-01-25 Trustees Of Dartmouth College Binding agents specific for IgA receptor
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies

Also Published As

Publication number Publication date
ATE373017T1 (de) 2007-09-15
WO2001009186A3 (en) 2001-05-31
AU779116B2 (en) 2005-01-06
JP4308470B2 (ja) 2009-08-05
MXPA02000960A (es) 2002-07-02
AU6235800A (en) 2001-02-19
KR100816958B1 (ko) 2008-03-26
CA2381565A1 (en) 2001-02-08
JP2007119485A (ja) 2007-05-17
KR20020047103A (ko) 2002-06-21
WO2001009186A2 (en) 2001-02-08
EP1212366B1 (de) 2007-09-12
DE60036388D1 (de) 2007-10-25
JP2003522128A (ja) 2003-07-22
HK1049170A1 (zh) 2003-05-02
CN1268645C (zh) 2006-08-09
CN1382157A (zh) 2002-11-27
EP1212366A2 (de) 2002-06-12

Similar Documents

Publication Publication Date Title
IL147766A0 (en) Therapeutic compounds comprised of anti-fc receptor binding agents
Ingram et al. Anti–CTLA-4 therapy requires an Fc domain for efficacy
Khera et al. Pharmacokinetic and immunological considerations for expanding the therapeutic window of next-generation antibody–drug conjugates
Maruani et al. A plug-and-play approach for the de novo generation of dually functionalized bispecifics
Cai et al. Synthetic multivalent glycopeptide‐lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells
CA2093022C (en) Targeted immunostimulation with bispecific reagents
Aluri et al. A hybrid protein–polymer nanoworm potentiates apoptosis better than a monoclonal antibody
Palitzsch et al. A synthetic glycopeptide vaccine for the induction of a monoclonal antibody that differentiates between normal and tumor mammary cells and enables the diagnosis of human pancreatic cancer
Stirnemann et al. Sustained activation and tumor targeting of NKT cells using a CD1d–anti-HER2–scFv fusion protein induce antitumor effects in mice
Glaffig et al. A synthetic MUC1 anticancer vaccine containing mannose ligands for targeting macrophages and dendritic cells
Oude Munnink et al. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F (ab′) 2 uptake in SKBR3 tumor xenografts
PH12013500858A1 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments that specifically bind cd 154 and uses thereof
WO2006002438A3 (en) Human monoclonal antibodies to fc gamma receptor i (cd64)
KR20200085942A (ko) 페르투주맙 변이체 및 그의 평가
Cho et al. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells
Gilabert-Oriol et al. Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells
MX2021010003A (es) Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
WO1998023646A2 (en) Binding agents specific for iga receptor
US20180271997A1 (en) Methods and Reagents to Treat Tumor and Cancer
WO2020132366A4 (en) T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
Fletcher et al. Formation of immune complexes with a tetanus-derived B cell epitope boosts human T cell responses to covalently linked peptides in an ex vivo blood loop system
Leal et al. Preclinical development of an anti-5T4 antibody–drug conjugate: pharmacokinetics in mice, rats, and NHP and tumor/tissue distribution in mice
WO2018231661A1 (en) Methods and reagents to treat tumor and cancer
Hong et al. Chemoenzymatic Synthesis of a Rhamnose‐Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy
CZ43798A3 (cs) Fúzní proteiny, způsob jejich přípravy a farmaceutický přípravek, který je obsahuje